• 1
    Kreuzer M, Kreienbrock L, Gerken M, et al. Risk factors for lung cancer in young adults. Am J Epidemiol. 1998; 147: 10281037.
  • 2
    Kreuzer M, Kreienbrock L, Muller KM, Gerken M, Wichmann E. Histologic types of lung carcinoma and age at onset. Cancer. 1999; 85: 19581965.
  • 3
    Gadgeel SM, Ramalingam S, Cummings G, et al. Lung cancer in patients <50 years of age: the experience of an academic multidisciplinary program. Chest. 1999; 115: 12321236.
  • 4
    Cote ML, Kardia SL, Wenzlaff AS, Land SJ, Schwartz AG. Combinations of glutathione S-transferase genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Carcinogenesis. 2005; 26: 811819.
  • 5
    Taioli E, Gaspari L, Benhamou S, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol. 2003; 32: 6063.
  • 6
    Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States) [published erratum appears in Cancer Causes Control. 1998;9:126]. Cancer Causes Control. 1997; 8: 544553.
  • 7
    Jourenkova-Mironova N, Wikman H, Bouchardy C, et al. Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenetics. 1998; 8: 495502.
  • 8
    Le Marchand L, Sivaraman L, Pierce L, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 1998; 58: 48584863.
  • 9
    London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst. 1995; 87: 12461253.
  • 10
    Saarikoski ST, Voho A, Reinikainen M, et al. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer. 1998; 77: 516521.
  • 11
    Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999; 91: 11941210.
  • 12
    Fields WR, Morrow CS, Doss AJ, Sundberg K, Jernstrom B, Townsend AJ. Overexpression of stably transfected human glutathione S-transferase P1-1 protects against DNA damage by benzo[a]pyrene diol-epoxide in human T47D cells. Mol Pharmacol. 1998; 54: 298304.
  • 13
    Nakajima T, Elovaara E, Anttila S, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis. 1995; 16: 707711.
  • 14
    Ryberg D, Skaug V, Hewer A, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997; 18: 12851289.
  • 15
    Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998; 19: 275280.
  • 16
    Kihara M, Noda K. Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers. Cancer Lett. 1999; 137: 5360.
  • 17
    Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics. 1998; 8: 2731.
  • 18
    To-Figueras J, Gene M, Gomez-Catalan J, et al. Genetic polymorphism of glutathione S-transferase P1 gene and lung cancer risk. Cancer Causes Control. 1999; 10: 6570.
  • 19
    Katoh T, Kaneko S, Takasawa S, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics. 1999; 9: 165169.
  • 20
    Massachusetts Department of Public Health. Massachusetts Tobacco Survey. Available at URL: (accessed May 20, 2006).
  • 21
    Wiencke JK, Thurston SW, Kelsey KT, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung [see comments]. J Natl Cancer Inst. 1999; 91: 614619.
  • 22
    Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996; 5: 687692.
  • 23
    Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons, Inc.; 2000.
  • 24
    Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000; 9: 328.
  • 25
    SAS Institute, Inc. SAS/Stat User's Guide. Version 6, 4th ed. Cary, NC: SAS Institute, Inc.; 1998.
  • 26
    Bailey-Wilson JE, Sellers TA, Elston RC, Evens CC, Rothschild H. Evidence for a major gene effect in early-onset lung cancer. J La State Med Soc. 1993; 145: 157162.
  • 27
    Gauderman WJ, Morrison JL. Evidence for age-specific genetic relative risks in lung cancer. Am J Epidemiol. 2000; 151: 4149.
  • 28
    Yang P, Schwartz AG, McAllister AE, Swanson GM, Aston CE. Lung cancer risk in families of nonsmoking probands: heterogeneity by age at diagnosis. Genet Epidemiol. 1999; 17: 25373.
  • 29
    Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res. 1998; 154: 4785.
  • 30
    Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S. Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis. 1998; 19: 813817.
  • 31
    Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 1998; 58: 52915293.
  • 32
    Cheng TJ, Christiani DC, Xu X, Wain JC, Wiencke JK, Kelsey KT. Glutathione S-transferase mu genotype, diet, and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cancer Epidemiol Biomarkers Prev. 1995; 4: 535542.
  • 33
    Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. J Natl Cancer Inst. 2000; 92: 154160.
  • 34
    London SJ, Daly AK, Fairbrother KS, et al. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism [see comments]. Cancer Res. 1995; 55: 60356037.
  • 35
    Nyberg F, Hou SM, Hemminki K, Lambert B, Pershagen G. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev. 1998; 7: 875883.
  • 36
    Persson I, Johansson I, Lou YC, et al. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer. 1999; 81: 325329.
  • 37
    To-Figueras J, Gene M, Gomez-Catalan J, et al. Glutathione-S-transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996; 5: 337342.
  • 38
    Casarett LJ, Klaassen CD, Amdur MO, Doull J. Casarett and Doull's Toxicology: the Basic Science of Poisons. New York: McGraw-Hill Health Professions Division; 1996.
  • 39
    Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997; 18: 641644.